Abstract:Introduction: Medicine innovation is crucial in promoting the sustainable development of medicine undertakings, which has significant economic and social benefits. China is the main force in global medicine consumption, with a huge demand for innovative medicines. Thus, the Chinese government releases a series of policies aimed at providing scientific and reasonable guidance for medicine innovation. However, there is inadequate quantitative evaluation and comparison of various medicine innovation policies in the existing studies. Methods: This paper adopts the approach of text mining and the Policy Modeling Consistency Index (PMC-Index) model to construct an evaluation system and then quantitatively evaluates and compares the traditional Chinese medicine innovation policies (TCMIPs), the biological medicine innovation policies (BMIPs), and the multiple medicine innovation policies (MMIPs) in China. Results: The results indicate that: (1) The three types of drug innovation policies have similarities in content and goal through comparative analysis of high-frequency words, while they also have their own characteristics. (2) The average PMC-Index of 29 TCMIPs is 5.77, which has the highest policy bad rate (21%); the average PMC-Index of 12 BMIPs is 6.21, which has the highest policy good rate (92%); moreover, the average PMC-Index of 35 MMIPs is 6.06, which has the highest policy excellence rate (26%). (3) The BMIPs, MMIPs, and TCMIPs have similar scores on policy object, policy orientation, policy timeliness, policy evaluation, and policy accessibility, while they differ significantly mainly on policy nature, incentive method, policy function, policy issuing agency, and policy instrument. Discussion: This study contributes to a comprehensive understanding of medicine innovation policies in China, in order to provide theoretical support for future policy formulation and optimization in the medicine industry. Moreover, we expand the application scenarios of policy diffusion theory.

Quantitative Evaluation of the Performance of Incentive Policy Institution in Biomedical Innovation

Monetary Incentives and Innovation in Chinese SMEs

Quantitative evaluation of the medicine innovation policy in China: based on the PMC-Index model

International Performance of Chinese Institutes in Different Disciplines——A Bibliometric View

Construction and Application of Evaluation Index System for Intellectual Property Policy in China

An entropy-based indicator system for measuring the potential of patents in technological innovation

Incentive effects of government subsidy on technological innovation: Evidence from pharmaceutical industry

The Performance of China'S Biomedical Innovation: A Scientometric Analysis

Introduction of Performance Evaluation to Research Management in Medical Institutions

Primary Investigation of the Indicators of Quality Evaluation on the Chinese Drug Patent

Research on Impact Mechanism of Innovation Policy in the Framework of Institutional Strategic Theory——Empirical Study on Biomedical High-tech Enterprises in Jiangsu Province

Measurement of Policy, Coordination of Policy and Economic Performance:An Empirical Study on Innovation Policy (1978-2006)

Quantitative Evaluation Innovation Policies of the State Council——based on the PMC-Index Model

Patent Quality Evaluation Index:an Case of Chinese Bio-pharmaceutical Industry

Study of Incentive Mechanism in Scientific Research

Research on Innovation Country Evaluation Indicator System

Enhancing China’s Incentive System for Scientific Innovation: A Review and Recommendations

Innovation Index Evaluation and Analysis for Chinese Universities in 2012

Research on the incentive mechanism of profit allocation in the industry-university-institute collaboration innovation

Analysis of Biopharmaceutical Innovation Investment in China and Its Policy Causes——On the Basis of the Status Quo of Innovation Investment in United States, Europe and China by Empirical Evaluation

Influence Mechanism of Government′s Innovation Policies on Firm′s Innovation Performance